Dual inhibition of V600EBRAF and the PI3K/AKT/mtor pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism

Cancer Letters

Volumn 314, Issue 2, 2012, Pages 244-255

  Sánchez Hernández, Irene ^a   Baquero, Pablo ^a   Calleros, Laura ^a   Chiloeches, Antonio ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Apoptosis; BRAF; MEK ERK; Melanoma; PI3K AKT mTOR

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B RAF KINASE; GLUTAMIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SORAFENIB; VALINE; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; MELANOMA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84855744813     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.037     Document Type: Article

References (46)

1. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, P.A. Futreal, Mutations of the BRAF gene in human cancer, Nature 417 (2002) 949-954.
2. D.A. Tuveson, B.L. Weber, M. Herlyn, BRAF as a potential therapeutic target in melanoma and other malignancies, Cancer Cell 4 (2003) 95-98.
3. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford, R. Marais, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell 116 (2004) 855-867.
4. M. Karasarides, A. Chiloeches, R. Hayward, D. Niculescu-Duvaz, I. Scanlon, F. Friedlos, L. Ogilvie, D. Hedley, J. Martin, C.J. Marshall, C.J. Springer, R. Marais, B-RAF is a therapeutic target in melanoma, Oncogene 23 (2004) 6292-6298.
5. C. Cohen, A. Zavala-Pompa, J.H. Sequeira, M. Shoji, D.G. Sexton, G. Cotsonis, F. Cerimele, B. Govindarajan, N. Macaron, J.L. Arbiser, Mitogen-actived protein kinase activation is an early event in melanoma progression, Clin. Cancer Res. 8 (2002) 3728-3733.
6. S.R. Hingorani, M.A. Jacobetz, G.P. Robertson, M. Herlyn, D.A. Tuveson, Suppression of BRAF(V599E) in human melanoma abrogates transformation, Cancer Res. 63 (2003) 5198-5202.
7. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, N.K. Haass, K. Sproesser, L. Li, K.S. Smalley, D. Fong, Y.L. Zhu, A. Marimuthu, H. Nguyen, B. Lam, J. Liu, I. Cheung, J. Rice, Y. Suzuki, C. Luu, C. Settachatgul, R. Shellooe, J. Cantwell, S.H. Kim, J. Schlessinger, K.Y. Zhang, B.L. West, B. Powell, G. Habets, C. Zhang, P.N. Ibrahim, P. Hirth, D.R. Artis, M. Herlyn, G. Bollag, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proc. Natl Acad. Sci. USA 105 (2008) 3041- 3046.
8. M.S. Cragg, E.S. Jansen, M. Cook, C. Harris, A. Strasser, C.L. Scott, Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic, J. Clin. Invest. 118 (2008) 3651-3659.
9. D.J. Panka, M.B. Atkins, J.W. Mier, Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma, Clin. Cancer Res. 12 (2006) 2371s-2375s.
10. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, P.B. Chapman, Inhibition of mutated, activated BRAF in metastatic melanoma, N. Engl. J. Med. 363 (2010) 809-819.
11. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, E.A. Burton, B. Wong, G. Tsang, B.L. West, B. Powell, R. Shellooe, A. Marimuthu, H. Nguyen, K.Y. Zhang, D.R. Artis, J. Schlessinger, F. Su, B. Higgins, R. Iyer, K. D'Andrea, A. Koehler, M. Stumm, P.S. Lin, R.J. Lee, J. Grippo, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.B. Chapman, K.T. Flaherty, X. Xu, K.L. Nathanson, K. Nolop, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature 467 (2010) 596- 599.
12. C. Sheridan, G. Brumatti, S.J. Martin, Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim, J. Biol. Chem. 283 (2008) 22128-22135.
13. Y.F. Wang, C.C. Jiang, K.A. Kiejda, S. Gillespie, X.D. Zhang, P. Hersey, Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1, Clin. Cancer Res. 13 (2007) 4934-4942.
14. K. Boisvert-Adamo, A.E. Aplin, Mutant B-RAF mediates resistance to anoikis via Bad and Bim, Oncogene 27 (2008) 3301-3312.
15. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, G.A. McArthur, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med. 364 (2011) 2507-2516.
16. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, R. Alvarado, M.J. Ludlam, D. Stokoe, S.L. Gloor, G. Vigers, T. Morales, I. Aliagas, B. Liu, S. Sideris, K.P. Hoeflich, B.S. Jaiswal, S. Seshagiri, H. Koeppen, M. Belvin, L.S. Friedman, S. Malek, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature 464 (2010) 431-435.
17. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, N. Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature 464 (2010) 427-430.
18. S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, M.E. Greenberg, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery, Cell 91 (1997) 231-241.
19. T.M. Gottlieb, J.F. Leal, R. Seger, Y. Taya, M. Oren, Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis, Oncogene 21 (2002) 1299-1303.
20. X. Zhang, N. Tang, T.J. Hadden, A.K. Rishi, Akt, FoxO and regulation of apoptosis, Biochim. Biophys. Acta (2010).
21. A. Carnero, The PKB/AKT pathway in cancer, Curr. Pharm. Des. 16 (2010) 34-44.
22. W.H. Chappell, L.S. Steelman, J.M. Long, R.C. Kempf, S.L. Abrams, R.A. Franklin, J. Basecke, F. Stivala, M. Donia, P. Fagone, G. Malaponte, M.C. Mazzarino, F. Nicoletti, M. Libra, D. Maksimovic-Ivanic, S. Mijatovic, G. Montalto, M. Cervello, P. Laidler, M. Milella, A. Tafuri, A. Bonati, C. Evangelisti, L. Cocco, A.M. Martelli, J.A. McCubrey, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health, Oncotarget 2 (2011) 135-164.
23. R. Gedaly, P. Angulo, J. Hundley, M.F. Daily, C. Chen, A. Koch, B.M. Evers, PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways, Anticancer Res. 30 (2010) 4951-4958.
24. K. Boisvert-Adamo, A.E. Aplin, B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis, Oncogene 25 (2006) 4848- 4856.
25. J.M. Stahl, A. Sharma, M. Cheung, M. Zimmerman, J.Q. Cheng, M.W. Bosenberg, M. Kester, L. Sandirasegarane, G.P. Robertson, Deregulated Akt3 activity promotes development of malignant melanoma, Cancer Res. 64 (2004) 7002-7010.
26. M. Cheung, A. Sharma, S.V. Madhunapantula, G.P. Robertson, Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development, Cancer Res. 68 (2008) 3429-3439.
27. Y. Shao, A.E. Aplin, Akt3-mediated resistance to apoptosis in B-RAFtargeted melanoma cells, Cancer Res. 70 (2010) 6670-6681.
28. C.C. Jiang, F. Lai, R.F. Thorne, F. Yang, H. Liu, P. Hersey, X.D. Zhang, MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720, Clin. Cancer Res. 17 (2011) 721-730.
29. K. Zitzmann, J. Ruden, S. Brand, B. Goke, J. Lichtl, G. Spottl, C.J. Auernhammer, Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease, Cancer Lett. 295 (2010) 100-109.
30. R.E. Schweppe, J.P. Klopper, C. Korch, U. Pugazhenthi, M. Benezra, J.A. Knauf, J.A. Fagin, L.A. Marlow, J.A. Copland, R.C. Smallridge, B.R. Haugen, Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification, J. Clin. Endocrinol. Metab. 93 (2008) 4331-4341.
31. R.J. Shaw, L.C. Cantley, Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature 441 (2006) 424-430.
32. B. Bedogni, S.M. Welford, A.C. Kwan, J. Ranger-Moore, K. Saboda, M.B. Powell, Inhibition of phosphatidylinositol-3-kinase and mitogenactivated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model, Mol. Cancer Ther. 5 (2006) 3071-3077.
33. J.Q. Cheng, C.W. Lindsley, G.Z. Cheng, H. Yang, S.V. Nicosia, The Akt/PKB pathway: molecular target for cancer drug discovery, Oncogene 24 (2005) 7482-7492.
34. J.S. Sebolt-Leopold, R. Herrera, Targeting the mitogen-activated protein kinase cascade to treat cancer, Nat. Rev. Cancer 4 (2004) 937-947.
35. M. Xing, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications, Endocr. Rev. 28 (2007) 742-762.
36. R. Leboeuf, J.E. Baumgartner, M. Benezra, R. Malaguarnera, D. Solit, C.A. Pratilas, N. Rosen, J.A. Knauf, J.A. Fagin, BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines, J. Clin. Endocrinol. Metab. 93 (2008) 2194-2201.
37. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J.M. Lobo, Y. She, I. Osman, T.R. Golub, J. Sebolt-Leopold, W.R. Sellers, N. Rosen, BRAF mutation predicts sensitivity to MEK inhibition, Nature 439 (2006) 358-362.
38. M. Baccarini, Second nature: biological functions of the Raf-1 "kinase", FEBS Lett. 579 (2005) 3271-3277.
39. N. Jin, T. Jiang, D.M. Rosen, B.D. Nelkin, D.W. Ball, Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer, J. Clin. Endocrinol. Metab. 94 (2009) 4107-4112.
40. C.W. Kinkade, M. Castillo-Martin, A. Puzio-Kuter, J. Yan, T.H. Foster, H. Gao, Y. Sun, X. Ouyang, W.L. Gerald, C. Cordon-Cardo, C. Abate-Shen, Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model, J. Clin. Invest. 118 (2008) 3051-3064.
41. M. Lopez-Fauqued, R. Gil, J. Grueso, J. Hernandez-Losa, A. Pujol, T. Moline, J.A. Recio, The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells, Int. J. Cancer 126 (2010) 1549- 1561.
42. K.F. Chen, H.L. Chen, W.T. Tai, W.C. Feng, C.H. Hsu, P.J. Chen, A.L. Cheng, Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells, J. Pharmacol. Exp. Ther. 337 (2011) 155-161.
43. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, A.K. Cipolla, B. Wubbenhorst, X. Xu, P.A. Gimotty, D. Kee, A.E. Santiago-Walker, R. Letrero, K. D'Andrea, A. Pushparajan, J.E. Hayden, K.D. Brown, S. Laquerre, G.A. McArthur, J.A. Sosman, K.L. Nathanson, M. Herlyn, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell 18 (2010) 683-695.
44. O.K. Mirzoeva, D. Das, L.M. Heiser, S. Bhattacharya, D. Siwak, R. Gendelman, N. Bayani, N.J. Wang, R.M. Neve, Y. Guan, Z. Hu, Z. Knight, H.S. Feiler, P. Gascard, B. Parvin, P.T. Spellman, K.M. Shokat, A.J. Wyrobek, M.J. Bissell, F. McCormick, W.L. Kuo, G.B. Mills, J.W. Gray, W.M. Korn, Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition, Cancer Res. 69 (2009) 565-572.
45. K.G. Lasithiotakis, T.W. Sinnberg, B. Schittek, K.T. Flaherty, D. Kulms, E. Maczey, C. Garbe, F.E. Meier, Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells, J. Invest. Dermatol. 128 (2008) 2013-2023.
46. K.S. Smalley, N.K. Haass, P.A. Brafford, M. Lioni, K.T. Flaherty, M. Herlyn, Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases, Mol. Cancer Ther. 5 (2006) 1136-1144.